Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor

Clinical Immunology

Volumn 131, Issue 2, 2009, Pages 308-316

  Kaymakcalan, Zehra ^a   Sakorafas, Paul ^a   Bose, Sahana ^a   Scesney, Susanne ^a   Xiong, Limin ^a   Hanzatian, Denise Karaoglu ^a   Salfeld, Jochen ^a   Sasso, Eric H ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Antibodies; Complement; Cytotoxicity; Human; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; IMMUNOGLOBULIN G1; INFLIXIMAB; IODINE 125; TUMOR NECROSIS FACTOR;

ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; BINDING AFFINITY; BINDING KINETICS; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CROHN DISEASE; DISSOCIATION CONSTANT; DRUG BINDING; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; ISOTOPE LABELING; MEMBRANE BINDING; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SPONDYLITIS; SURFACE PLASMON RESONANCE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; CELL MEMBRANE; COMPLEMENT ACTIVATION; HUMANS; IMMUNOGLOBULIN G; KINETICS; MEMBRANE PROTEINS; PROTEIN BINDING; RECEPTORS, TUMOR NECROSIS FACTOR; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 63749093322     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.01.002     Document Type: Article

References (32)

1. Sandborn W.J., Hanauer S.B., Katz S., Sadi M., Wolf D.G., Baerg R.D., Tremaine W.J., Johnson T., Diehl N.N., and Zinsmeister A.R. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121 (2001) 1088-1094
2. Wallis R.S., and Ehlers S. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin. Arthritis Rheum. 34 5 Suppl 1 (2005) 34-38
3. Ehlers S. Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF. Ann. Rheum. Dis. 62 Suppl 2 (2003) ii37-ii42
4. Lim W.C., and Hanauer S.B. Emerging biologic therapies in inflammatory bowel disease. Rev. Gastroenterol. Disord. 4 (2004) 66-85
5. Rigby W.F. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?. Nat. Clin. Pract. Rheumatol. 3 (2007) 227-233
6. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., and Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117 (2008) 244-279
7. Locksley R.M., Killeen N., and Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104 (2001) 487-501
8. Van den Brande J.M., Braat H., van den Brink G.R., Versteeg H.H., Bauer C.A., Hoedemaeker I., van Montfrans C., Hommes D.W., Peppelenbosch M.P., and van Deventer S.J. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 (2003) 1774-1785
9. Mitoma H., Horiuchi T., and Tsukamoto H. Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-[alpha]. Gastroenterology 126 (2004) 934-935
10. Nesbitt A., Fossati G., Bergin M., Stephens P., Stephens S., Foulkes R., Brown D., Robinson D., and Bourne T. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm. Bowel Dis. 13 (2007) 1323-1332
11. Mitoma H., Horiuchi T., Tsukamoto H., Tamimoto Y., Kimoto Y., Uchino A., To K., Harashima S., Hatta S., and Harada M. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 58 (2008) 1248-1257
12. Scallon B.J., Moore M.A., Trinh H., Knight D.M., and Ghrayeb J. Chimeric anti-TNF-[alpha] monoclonal antibody cA2 binds recombinant transmembrane TNF-[alpha] and activates immune effector functions. Cytokine 7 (1995) 251-259
13. Eissner G., Kirchner S., Lindner H., Kolch W., Janosch P., Grell M., Scheurich P., Andreesen R., and Holler E. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J. Immunol. 164 (2000) 6193-6198
14. Harashima S., Horiuchi T., Hatta N., Morita C., Higuchi M., Sawabe T., Tsukamoto H., Tahira T., Hayashi K., Fujita S., and Niho Y. Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells. J. Immunol. 166 (2001) 130-136
15. Eissner G., Kolch W., and Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev. 15 (2004) 353-366
16. Shen C., Assche G.V., Colpaert S., Maerten P., Geboes K., Rutgeerts P., and Ceuppens J.L. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment. Pharmacol. Ther. 21 (2005) 251-258
17. Rossol M., Meusch U., Pierer M., Kaltenhäuser S., Häntzschel H., Hauschildt S., and Wagner U. Interaction between transmembrane TNF and TNFR1/2 mediates the activation of monocytes by contact with T cells. J. Immunol. 179 (2007) 4239-4248
18. Perez C., Albert I., De Fay K., Zachariades N., Gooding L., and Kriegler M. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63 (1990) 251-258
19. Santora L.C., Kaymakcalan Z., Sakorafas P., Krull I.S., and Grant K. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal. Biochem. 299 (2001) 119-129
20. Scallon B., Cai A., Solowski N., Rosenberg A., Song X.Y., Shealy D., and Wagner C. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. 301 (2002) 418-426
21. Moosmayer D., Wajant H., Gerlach E., Schmidt M., Brocks B., and Pfizenmaier K. Characterization of different soluble TNF receptor (TNFR80) derivatives: positive influence of the intracellular domain on receptor/ligand interaction and TNF neutralization capacity. J. Interferon Cytokine Res. 16 (1996) 471-477
22. Frishman J.I., Edwards III C.K., Sonnenberg M.G., Kohno T., Cohen A.M., and Dinarello C.A. Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors. J. Infect. Dis. 182 (2000) 1722-1730
23. Kohno T., Tam L.T.T., Stevens S.R., and Louie J.S. Binding characteristics of tumor necrosis factor-fusion proteins vs anti-tumor necrosis factor mAbs. J. Investig. Dermatol. Symp. Proc. 12 (2007) 5-8
24. Rodríguez-Caballero A., García-Montero A.C., Bueno C., Almeida J., Varro R., Chen R., Pandiella A., and Orfao A. A new simple whole blood flow cytometry-based method for simultaneous identification of activated cells and quantitative evaluation of cytokines released during activation. Lab. Invest. 84 (2004) 1387-1398
25. Black R.A. Tumor necrosis factor-alpha converting enzyme. Int. J. Biochem. Cell Biol. 34 (2002) 1-5
26. Chokki M., Mitsuhashi H., and Kamimura T. Metalloprotease-dependent amphiregulin release mediates tumor necrosis factor-alpha-induced IL-8 secretion in the human airway epithelial cell line NCI-H292. Life Sci. 78 (2006) 3051-3057
27. Nii A., Sone S., Orino E., and Ogura T. Induction of a 26-kDa membrane-form tumor necrosis factor (TNF)-a in human alveolar macrophages. J. Leukoc. Biol. 53 (1993) 29-36
28. Bazzoni F., and Beutler B. The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 334 (1996) 1717-1725
29. Mascher B., Schlenke P., and Seyfarth M. Expression and kinetics of cytokines determined by intracellular staining using flow cytometry. J. Immunol. Methods 223 (1999) 115-121
30. Ferrante A., Staugas R.E., Rowan-Kelly B., Bresatz S., Kumaratilake L.M., Rzepczyk C.M., and Adolf G.R. Production of tumor necrosis factors alpha and beta by human mononuclear leukocytes stimulated with mitogens, bacteria, and malarial parasites. Infect. Immun. 58 (1990) 3996-4003
31. Fan J., Nishanian P., Breen E.C., McDonald M., and Fahey J.L. Cytokine gene expression in normal human lymphocytes in response to stimulation. Clin. Diagn. Lab. Immunol. 5 (1998) 335-340
32. Golay J., Lazzari M., Facchinetti V., Bernasconi S., Borleri G., Barbui T., Rambaldi A., and Introna M. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98 (2001) 3383-3389